2014 Q3：Chinese hospital market slow down
2015/1/11 E药经理人

     According to the IMS Health, in 2014 Q3, the total sales of Chinese hospital drug market reached RMB 161.73 billion (about USD 26 billion, only report the hospitals with ≥100 beds ), increasing 12% compare to the same period of 2013. The growth decline is partly because of the slowdown of TCM patent prescriptions.

     TCM patent prescription is the largest therapeutic field in Chinese hospital market. Its sales in 2014 Q3 were RMB 31.707 billion (about USD 5.1 billion), increasing 10.2%.

     Only two MNC drugs entered the top 10 best sold list in the quarter, and the top 3 are all from domestic players, which are Shenjie (Monosialotetrahexosylganglioside Sodium Injection) from Qilu Pharma, sales over RMB 100 million (about USD 16 million), Xueshuantong Injection (TCM) from Livzon, RMB 94.5 million (about USD 15.2 million) and Aodejin (Deproteinised Calf Blood Serum Injection) from Jingzhou Ahon Pharma, with revenues of RMB 87.4 million (about USD 14 million). Sanofi's Plavix placed the fourth.

    http://www.duyihua.cn
返回 E药经理人 返回首页 返回百拇医药